Ross Pacini, MD
Cardiovascular Disease · Lincoln, NENPI 1467636928
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.6% of the total across 85 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 23 manufacturers, the largest accounting for just 12.1% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $614 and has fallen 87.6% since, to $76 in 2025. That places this record below the midpoint for cardiovascular disease clinicians in NE, where the typical reported total is $1,663.
Across 85 payments — averaging $19.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$202
- E.r. Squibb & Sons, L.L.C.$200
- Medtronic$179
- Johnson & Johnson$154
- Novartis$129
- Boston Scientific$122
- plus $678 from 17 others
What the payments were for
- Food & beverage$1,657100%
- Entertainment$60%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 8 | $202 |
| E.r. Squibb & Sons, L.L.C. | 14 | $200 |
| Medtronic(2 entities) | 5 | $179 |
| Johnson & Johnson | 10 | $154 |
| Novartis | 7 | $129 |
| Boston Scientific | 8 | $122 |
| Bard Peripheral Vascular, Inc. | 1 | $108 |
| Amgen | 5 | $105 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 6 | $105 |
| AstraZeneca | 4 | $54 |
| Merck | 3 | $44 |
| Pfizer | 3 | $41 |
| Chiesi USA, Inc. | 1 | $38 |
| Altathera Pharmaceuticals LLC | 1 | $25 |
| Amryt Pharma Holdings Ltd | 1 | $22 |
| Artivion, Inc. | 1 | $21 |
| Bardy Diagnostics, Inc. | 1 | $21 |
| Tactile Systems Technology Inc | 1 | $19 |
| Angiodynamics, Inc. | 1 | $19 |
| Regeneron Healthcare Solutions, Inc. | 1 | $18 |
| Lantheus Medical Imaging, Inc. | 1 | $16 |
| Sanofi-aventis U.S. LLC | 1 | $16 |
| Hitachi Healthcare Americas Corp. | 1 | $6 |
How this compares
$1,663 in reported general payments places this provider in the 50th percentile of 97 cardiovascular disease providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XareltoRivaroxaban | 208 | $151,401 |
| EliquisApixaban | 209 | $147,119 |
| EntrestoSacubitril/Valsartan | 37 | $44,038 |
| FarxigaDapagliflozin Propanediol | 47 | $32,108 |
| JardianceEmpagliflozin | 18 | $12,204 |
| Praluent PenAlirocumab | 25 | $12,103 |
| Atorvastatin Calcium | 745 | $6,636 |
| Metoprolol Succinate | 371 | $6,086 |
| Ezetimibe | 231 | $5,090 |
| Amlodipine Besylate | 457 | $2,670 |
| Carvedilol | 400 | $2,512 |
| Rosuvastatin Calcium | 237 | $2,472 |
| Nebivolol Hcl | 39 | $1,725 |
| Lisinopril | 184 | $1,393 |
| Losartan Potassium | 181 | $1,297 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto | $154 | $151,401208 claims |
| PfizerEliquis | $41 | $147,119209 claims |
| NovartisEntresto | $129 | $44,03837 claims |
| AstraZenecaFarxiga | $54 | $32,10847 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 97 cardiovascular disease providers in Nebraska.
Other cardiovascular disease in Lincoln
- Robert PercellLincoln$918K
- Steven KruegerLincoln$388K
- Keith MillerLincoln$86K
- Wynn HunterLincoln$46K
- Gina MentzerLincoln$27K
- Rajeev AnchanLincoln$7K
- Kaliprasad AyalaLincoln$5K
- John SteuterLincoln$4K
- Rebecca RundlettLincoln$3K
- Omar NassLincoln$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.